Anyways, I head the full briefing and here are my thoughts.
Dr Treagus did not comment when asked whether there was a trail phase 3. he constantly alluded that we will be looking for FDA guidance on our next stage of development.
He clearly mentions that there will be 2 separate applications.
1) Orphan drug designation.
2) breakthrough therapy.
Given the results that we have achieved, he are quite confident that NNZ-2566 should be granted the orphan drug designation. He mentioned that breakthrough therapy will be a separate application and he said we cannot guarantee that we will be granted the BT.
Following is the chart re the approval if BT is granted. We do not need a phase 3.
Source
The U.S. Food and Drug Administration’s (FDA) new breakthrough therapy designation represents perhaps the most important effort to date to reduce the time required to bring new drugs to market. According to the FDA a breakthrough therapy is a drug that is:
The breakthrough therapy designation allows for early and positive awareness of a drug’s therapeutic value, signaling that the product delivers substantial improvement on at least one clinical endpoint.
- Intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition and
- That may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development, as indicated by preliminary clinical evidence.
My impression was that Dr Treagus, Joe and Larry were hopeful of BT grant allowing us to avoid the phase 3 and thus did not comment on the whether there will be phase 3 of RETT or not.
Dr Treagus also said that a large number of Pharmas are increasingly monitoring our success but he is fully committed to completing all the trials at hand.
A full update of all the remaining trial and progress will be given before the end of the year.
Table of BT approval and parent companies.
Column 1 Column 2 Column 3 Column 4 0 Drug Name FDA Approval Date Sponsor Company Indication 1 Gazyva (Obinutuzumab) 11.01.13 Genentech Chronic Lymphocytic Leukemia (CLL) 2 Imbruvica (Ibrutinib) 11.13.13 Pharmacyclics Mantle Cell Lymphoma (MCL) 3 Sovaldi (Sofosbuvir) 12.06.13 Gilead Sciences Hepatitis C 4 Kalydeco (Ivacaftor)** 02.21.14 Vertex Pharmaceuticals 8 additional mutations in CFTR gene for Cystic Fibrosis (CF) 5 Arzerra (Ofatumumab) *** 04.17.14 GlaxoSmithKline In combination with Chlorambucil for previously untreated Patients with CLL for whom fludarabine-based therapy is considered inappropriate 6 Zykadia (Ceritinib) 04.29.14 Novartis Metastatic ALK+ NSCLC 7 Zydelig (Idelalisib) 07.23.14 Gilead Sciences Chronic Lymphocytic Leukemia (CLL) 8 Imbruvica (Ibrutinib)* 07.28.14 Pharmacyclics Chronic Lymphocytic Leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion) 9 Promacta (Eltrombopag)** 08.26.14 GlaxoSmithKline Severe Aplastic Anemia (SAA) with insufficient response to Immunosupporessive Therapy (IST) 10 Keytruda (Pembrolizumab) **** 09.04.14 Merck Unresectable/ Metastatic Melanoma, disease progression, & have BRAF V600 mutation, following treatment with Yervoy & a BRAF inhibitor 11 Harvoni (Ledipasvir /Sofosbuvir) 10.10.14 Gilead Sciences Genotype 1 Chronic HCV 12 Esbriet (Pirfenidone) 10.15.14 InterMune Idiopathic Pulmonary Fibrosis 13 Ofev (Nintedanib) 10.15.14 Boehringer Ingelheim Pharmaceuticals Idiopathic Pulmonary Fibrosis 14 Trumenba (Meningococcal Group B Vaccine) ***** 10.29.14 Pfizer Meningococcal B Disease
- Forums
- ASX - By Stock
- NEU
- Watch this space...
Watch this space..., page-36
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$20.17 |
Change
0.070(0.35%) |
Mkt cap ! $2.578B |
Open | High | Low | Value | Volume |
$20.39 | $20.53 | $20.14 | $4.102M | 202.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 249 | $20.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.31 | 790 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 249 | 20.150 |
5 | 650 | 20.000 |
3 | 776 | 19.900 |
6 | 2760 | 19.800 |
1 | 400 | 19.780 |
Price($) | Vol. | No. |
---|---|---|
20.680 | 888 | 1 |
20.800 | 500 | 1 |
20.900 | 500 | 1 |
21.000 | 2200 | 3 |
21.200 | 611 | 2 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |